PARP activity was not associated with ATM dysfunction or levels of oxidative DNA damage and the potent PARP inhibitor talazoparib inhibited the growth of patient derived CLL cells at low concentrations, even in cells with functional HRR. The gene discussed is PARP1; the disease is B-cell chronic lymphocytic leukemia.